Perth-Based Linear Clinical Research Selects Medrio for First Adoption of EDC

Share Article

Australian research company Linear Clinical Research has selected Medrio for their first clinical trial using electronic data capture, offering positive feedback on Medrio’s software soon after going live. The selection strengthens Medrio’s foothold in APAC, an increasingly popular destination for clinical research.

News Image
The [Medrio] system has not faltered once. It's been so easy and user-friendly.

Linear Clinical Research, a research company based in Perth, Australia, has selected Medrio, a Software as a Service (SaaS) company providing cutting-edge electronic data capture (EDC) services to clinical trials, as their data management solution for their research. Medrio is the first EDC tool the researchers at Linear have used as the company transitions from paper-only clinical trials. The decision came at the end of a meticulous and comprehensive vendor selection process in which Linear evaluated a total of 74 EDC vendors.

Several factors contributed to the decision at Linear to utilize Medrio for their initial investment in EDC. Linear’s research team notes that the simplicity, agility, and user-friendliness of Medrio’s software has played a major role in easing their transition away from paper, allowing researchers with little to no EDC background to quickly become comfortable and fluent in the technology. Medrio’s training services were of particular utility to the researchers at Linear as they got their first study in Medrio up and running. In addition, Linear and Medrio are united by their specialization in the early phases of clinical research: Linear is the only research facility in Western Australia focused primarily on early phase clinical trials, and Medrio is the eClinical industry leader for the early phases.

With their partnership with Linear, Medrio is strengthening its foothold in the Asia Pacific (APAC) region, which has emerged in recent years as a hub of clinical research. Australia, in particular, has earned substantial attention from clinical trial sponsors due to its favorable regulations, cost efficiency, and reduced approval timelines. APAC countries where Medrio has provided its services include China, Japan, South Korea, and others.

“Australia is an attractive destination for clinical research, but we have to maintain our position as the most desirable and innovative clinical trial destination in the world,” commented Dr. Michael Winlo, CEO of Linear Clinical Research. “This is why Linear is making a substantial investment to support EDC.”

Dr. Winlo notes than transitioning from paper-only studies to EDC studies will allow his team to:

  •     Quicken the process of drug development
  •     Be more quickly alerted to adverse events, reducing the risk of harm or illness to subjects and patients
  •     Improve patient engagement efforts by allowing patients to track trial data themselves
  •     Improve data accuracy
  •     Localize forms so that patients can read information in their own language

“Trials are getting larger and more complicated and there is more competition among drug companies who bring their therapies to market faster than ever before,” commented Medrio founder and CEO Mike Novotny. “This technology can speed up the whole process.”

Since their first study in Medrio went live, the feedback from Linear has been positive. “The system has not faltered once,” noted Simone Knab, Head of Clinical Operations at Linear. “It’s been so easy and user-friendly.”

About Dr. Michael Winlo and Linear Clinical Research
Dr. Michael Winlo has a Bachelor of Medicine, Bachelor of Surgery, and an MBA from Stanford University. He heads up the Linear Clinical Research facility in Perth, which is a global leader in early phase clinical trials.

Based at the Harry Perkins Institute of Medical Research, Linear Clinical Research is a 32-bed facility with 24-hour medical emergency team coverage. Regulatory standards in Australia mean that clinical trials conducted at Linear are completed six months faster than in the US and often at a third of the cost. Since it was established in 2010, there have been 170 clinical trials on general participants and over 180 oncology patients enrolled into world-first clinical trials.

To find out more about the use of electronic data capture for clinical trials visit http://www.linear.org.au.

About Medrio
Medrio offers an integrated eClinical SaaS platform that reduces costs and timelines in clinical research, accelerating the market arrival of life-saving medical products and facilitating a greater industry-wide output of clinical trials. Medrio’s cloud-based, affordable, and user-friendly EDC and eSource products empower researchers to break their reliance on paper-based clinical data management. Users can build studies in days instead of months with a simple drag-and-drop interface, and enjoy access to a support staff that takes pride in crafting effective and reliable products and is backed by a top-tier customer satisfaction rating. Medrio is the EDC industry’s momentum leader, outgrowing the industry by a factor of 4 and the Phase I study market by a factor of 11. Medrio has served over 3,000 clinical trials of all phases and therapeutic areas and submitted to all major regulatory bodies across the globe.

For more information, or to schedule an online demonstration or request a free trial, please visit http://www.medrio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nick O'Brien
Medrio
+1 4152769292
Email >